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Anemia is a frequently encountered complication in cancer, and is associated with fatigue and reduced quality of life. Retro-
spective analyses of data from patients with hematological malignancies and solid tumors provide evidence that a low baseline
hemoglobin (Hb) level is a prognostic factor for poor outcome. Moreover, in some situations, low Hb is a negative predictive
parameter in chemotherapy. The adverse impact of anemia has been documented in patients with lymphomas and leukemias, as
well as in those with non–small-cell lung cancer, ovarian cancer, cervical cancer, renal cell carcinoma, head and neck cancer and
other solid tumors. Studies in animal models support the role of low Hb levels as a negative prognostic and predictive factor.
Although prospective clinical trials are still needed to conﬁrm that Hb levels aﬀect outcome, the available evidence suggests that
there is more than one reason to pay attention to Hb levels in cancer patients: increasing Hb not only corrects anemia and thereby
improves physical functioning and quality of life, but also may improve clinical outcomes.
# 2003 Elsevier Ltd. All rights reserved.Keywords: Anemia; Cancer; Hemoglobin; Prognostic; Predictive1. Introduction
The ultimate goal in cancer treatment is to cure the
disease, but when this is not possible, the goal becomes
providing the best palliation. The most important
outcomes of treatment are overall survival (OS) and
disease-free survival (DFS). However, longer progres-
sion-free survival (PFS), increased response rates and
improved quality of life (QOL) are also important
beneﬁts of palliative cancer therapy. These outcomes
are inﬂuenced by various baseline parameters that are
typically related to the patient, such as performance
status, or related to the tumor, such as its histology. How-
ever, the speciﬁc and dominant factors that inﬂuence
outcome in individual patients are often unclear.
Prognostic factors are variables that independently
inﬂuence outcome, whereas predictive factors are those
that independently inﬂuence the response to a certain
intervention. Because prognostic factors suggest the
future course of disease, they are often helpful inmaking treatment decisions. Moreover, prognostic fac-
tors are useful in the design and analysis of clinical
trials, and are often used as a basis for stratiﬁcation
procedures. In this paper, the value of hemoglobin (Hb)
level as a prognostic and/or predictive factor will be
considered.
Anemia is a frequently encountered complication in
cancer, and may arise as a direct eﬀect of the malig-
nancy or its treatment [1]. Anemia due to the cancer
itself, categorized as anemia of chronic disease, is often
seen before or at diagnosis of the underlying cancer and
may precede the start of myelosuppressive radiation
therapy or chemotherapy [2,3]. Chronic anemia of
cancer may develop as a result of disease-stimulated
production of inﬂammatory cytokines (e.g. interferons,
interleukin-1, tumor necrosis factor) [1–4]. Over-
production of cytokines can inhibit erythropoiesis by
reducing erythropoietin production and the responsive-
ness of erythroid progenitor cells, shortening the life
span of red blood cells, and impairing iron utilization.
Other possible causes of chronic anemia of cancer
include mechanical displacement of normal erythro-
poietic bone marrow by tumor tissue, marrow necrosis,
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loss or bleeding in the tumor, among others. Cancer
treatment may exacerbate this type of anemia or may be
the sole cause of anemia in cancer patients. Although
low Hb levels are strongly associated with disease-
related fatigue and decreased QOL, the relationship
between anemia and cancer is complex and less well
understood.
An increasing body of evidence obtained over the last
decade suggests that anemia is correlated with poor
clinical outcome in cancer patients [5]. Studies show
that tumor hypoxia contributes to more aggressive
behavior of cancer cells and may compromise the
response to cancer treatment [6–9].2. Hemoglobin level as a prognostic factor in
hematological malignancies
2.1. Non-Hodgkin’s lymphoma
Anemia occurs frequently in patients with non-
Hodgkin’s lymphoma (NHL). A retrospective analysis
of 1077 patients in France with various histological
NHL subtypes, most commonly diﬀuse–large-cell
lymphoma (40%) and follicular lymphoma (19%),
found anemia to be present in 341 (32%) patients before
treatment was started [10]. In this study, anemia was
deﬁned as an Hb level 412 g/dl in all men and in
women over 50 years, and a level 411 g/dl in women
under 50 years. The incidence of anemia varied accord-
ing to the NHL histology, being highest in those with
diﬀuse–large-cell lymphoma (39%) and lowest in those
with follicular lymphoma (17%). Moreover, the
incidence of anemia was higher in patients with bone
marrow involvement than in those without (37% versus
27%, respectively, P=0.0005).
In a univariate analysis of data from this study,
anemia was an adverse prognostic factor for both OS
and PFS (P <0.0001) [10]. Median OS was 47 and 146
months in patients with anemia and those with normal
Hb levels, respectively, whereas median PFS was 15 and
64 months, respectively. Anemia was associated with
shorter OS in all histological subtypes except marginal
zone lymphoma. Anemia remained a signiﬁcant adverse
prognostic factor for OS and PFS in the multivariate
analysis for the population as a whole (P=0.0001 and
P=0.0048, respectively), and for those with bone marrow
involvement (P=0.007 and P=0.005, respectively), but
not for those without bone marrow involvement. Nota-
bly, addition of anemia to the International Prognostic
Index (IPI) signiﬁcantly improved the prognostic
signiﬁcance of this index for OS and PFS (both
P=0.0004).
In contrast, in a recent retrospective analysis of 987
follicular lymphoma patients in Italy, only 8% had low
Hb levels (<12 g/dl for men and <10 g/dl for women)before the start of treatment [11]. Patients received a
variety of treatments (e.g. single-agent chemotherapy
with or without a-interferon, multi-agent chemo-
therapy, radiation therapy alone, no initial therapy). In
the univariate analysis, low Hb levels, compared with
higher Hb levels, were associated with poorer 5-year
(60% versus 83%, respectively) and 10-year (53%
versus 65%, respectively) survival rates (P=0.0001). Of
the 11 variables signiﬁcantly associated with poorer
outcome in the univariate analysis, only six proved to be
signiﬁcant in the multivariate analysis: age >60 years,
male gender, number of extranodal sites (two or more),
B symptoms (unexplained high temperature, heavy
night sweats, and loss of >10% of total body weight),
elevated serum lactate dehydrogenase (LDH) levels, and
high erythrocyte sedimentation rate (ESR). Using the
six variables, it was possible to stratify patients into low
(0–1 variables), intermediate (2 variables), or high (53
variables) risk groups with diﬀerent 10-year survival
rates (65%, 54%, and 11%, respectively; P <0.0001).
In this study, Hb level was a prognostic factor in the
univariate analysis, but in the multivariate analysis
it was not established as an independent prognostic
parameter.
Mantle cell lymphoma is an aggressive subtype of
NHL with a high rate of relapse after initial treatment.
Once relapse occurs, the disease becomes even more
aggressive and more refractory to treatment and is
inevitably terminal, with a median survival of 3–4 years.
Two retrospective studies of mantle-cell lymphoma have
considered Hb levels as one of the prognostic factors.
The ﬁrst study analysed 34 patients whose cancer had
been reclassiﬁed as mantle cell lymphoma [12]. These
patients were part of a larger group of 69 patients
originally classiﬁed as Working Formulation groups B
and E. The majority (30/34) had received anthracycline
therapy. Median OS was 41 months for the mantle cell
lymphoma group; univariate analysis showed that
longer OS was associated with a nodular histological
pattern (P=0.054), IPI score under 2 (P=0.0027),
response to therapy (P=0.0125), and higher Hb levels
(>12 g/dl; P=0.02). Notably, response to therapy,
which was already a prognostic parameter by itself, was
inﬂuenced only by Hb level (P=0.054), demonstrating
that the Hb level was also a predictive factor. The
second study considered the outcomes of 121 patients
with mantle cell lymphoma who were treated at a
French hospital between 1979 and 1997 [13]. 37% of the
patients had anemia at diagnosis. In the univariate
analysis, Hb levels were not associated with response to
initial treatment or PFS; however, higher Hb levels
(>12 g/dl) were associated with a signiﬁcantly longer
OS (P=0.014). Other factors associated with a longer
survival in this analysis included age under 70 years
(P=0.0075), good performance status (P=0.001),
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extranodal sites (P=0.00034), no spleen enlargement
(P=0.04), absence of peripheral blood involvement
(P=0.0017) and normal serum LDH and b2-micro-
globulin levels (P=0.009 and P=0.04, respectively). In
the multivariate analysis, only low Hb level, age >70
years, poor performance status, blood involvement and
bulky disease were associated with a poorer OS.
Taken together, these studies suggest that Hb level is
a prognostic factor for OS in NHL, particularly for
those with an aggressive histological subtype, and is a
predictive factor in mantle cell lymphoma.
2.2. Hodgkin’s disease
The International Prognostic Factors Project on
Advanced Hodgkin’s Disease considered the prognostic
value of 19 demographic and clinical variables at diag-
nosis on PFS [14]. Data were obtained retrospectively
from 25 centers for 5141 patients who were treated with
combination chemotherapy with or without radiation
therapy for advanced Hodgkin’s disease. 33% of patients
had Hb levels of 10.1–12.0 g/dl at diagnosis and 17%
had levels410.0 g/dl. Complete data for all 19 variables
were available for 1681 patients. In the univariate
analysis, low Hb level was inversely related to PFS and
OS (both P <0.001). Several other variables were
signiﬁcantly related to both outcomes, including age,
gender, Ann Arbor stage, liver or inguinal involvement,
systemic symptoms, ESR, serum albumin, alkaline
phosphatase and white cell, platelet and lymphocyte
counts. However, using the multivariate Cox model,
only seven factors had adverse prognostic signiﬁcance
for PFS: Hb <10.5 g/dl (P=0.006), serum albumin <4
g/dl (P <0.001), male gender (P=0.001), stage IV disease
(P=0.011), age of 45 years or older (P=0.001), leuko-
cytosis (white cell count515 000/mm3) (P=0.001), and
lymphocytopenia <600/mm3 (P=0.002). Using this
model, PFS at 5 years was inversely related to the
number of prognostic factors, ranging from 84% for
those with no factors to 42% for those with ﬁve or more
factors. Five-year OS rates ranged from approximately
90% for patients with no prognostic factor or only one
factor to 56% for those with ﬁve or more factors.
Two other studies highlight the prognostic value of
Hb levels in Hodgkin’s disease. A retrospective eval-
uation of the medical records of 87 patients who
presented at the M.D. Anderson Cancer Center with
stage I or II subdiaphragmatic Hodgkin’s disease found
that Hb levels 412 g/dl (P=0.02), albumin level <3.5
g/dl (P=0.0002), age over 40 years (P <0.00001), B
symptoms (P=0.001) and nodular sclerosis or mixed
cellular histology (P=0.001) independently predicted
poorer OS in a univariate analysis [15]. On multivariate
analysis, decreased Hb levels, age greater than 40 years,
and nodular sclerosis or mixed cellularity histology were
independent risk factors for OS. Most of the patients inthis analysis had been treated with radiotherapy either
alone (69%) or in combination with chemotherapy
(26%), and most had pelvic or abdominal disease (64%)
at presentation. Approximately 15% had Hb levels of
less than 12 g/dl prior to treatment. In a pediatric study,
202 children with Hodgkin’s disease received four cycles
of a chemotherapy regimen devoid of anthracyclines
and alkylating agents (vinblastine, bleomycin, etopo-
side, and prednisone) followed by 20 Gy of radiation
therapy [16]. After a median follow-up of 74 months,
the 5-year OS and event-free survival rates were 98%
and 91%, respectively. In the multivariate analysis,
Hb levels <10.5 g/dl (P=0.003), ‘b’ biologic class
(P=0.06), and nodular sclerosis histology (P=0.002)
predicted poorer event-free survival. These studies indi-
cate that the Hb level holds prognostic signiﬁcance in
both adult and paediatric Hodgkin’s disease.
2.3. Acute myeloid leukaemia
The prognostic value of Hb levels in patients with
refractory and relapsed acute myeloid leukaemia
(AML) was assessed in 254 patients undergoing S-HAM
(sequential high-dose cytosine arabinoside and mitox-
antrone) salvage chemotherapy [17]. The achievement of
a second complete remission was related to Hb level
(P=0.0197), absence of refractory disease (P=0.0118),
duration of ﬁrst complete remission (P=0.0176), and
lowered white blood cell (P=0.0296) and blast <5%
(P=0.0315) counts in the univariate analysis but was
signiﬁcantly associated only with the Hb level
(P=0.0457) in the multivariate analysis. Also, in the
multivariate analysis, overall survival was found to be
related only to bilirubin level (P=0.0166). A sub group
of 104 patients in whom karyotype analysis had been
conducted before ﬁrst-line therapy was evaluated
separately. In this sub group, unfavorable chromosomal
abnormalities were found to be the only factor related
to OS on multivariate analysis (P=0.036) and no factor
(including Hb) was signiﬁcantly associated with
achievement of complete remission in this analysis.
Thus, Hb level appears to be predictive of response to
salvage chemotherapy in refractory and relapsed AML,
but to not have prognostic signiﬁcance for OS.
Table 1 summarizes the eﬀect of low Hb levels on OS in
retrospective analyses of hematological malignancies.3. Hemoglobin level as a prognostic and predictive
factor in solid tumors
3.1. Non–small-cell lung cancer
The Southwest Oncology Group conducted a retro-
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(NSCLC) who were accrued to 14 phase II or III studies
from 1974 to 1988 [18]. In the multivariate analysis of
2290 patients for whom there were complete data, the
only factors signiﬁcantly associated with a favorable OS
were good performance status, female sex, cisplatin-
based therapy (all P <0.00005) and age 570 years
(P=0.02). However, a second multivariate analysis was
conducted for a sub group of 362 patients with good
performance status who were enrolled in the more
recent studies. In this sub group, better OS was asso-
ciated with Hb levels 511 g/dl (P=0.001); normal
serum LDH (P=0.002) and calcium (P=0.007); a single
metastatic site (P=0.02); and cisplatin-based therapy
(P=0.05). Moreover, a recursive partitioning and
amalgamation analysis of 904 patients from recent
studies found that the best survival was achieved in
patients with good performance status who had Hb
levels >11 g/dl and were older than 47 years.
A prospective study was conducted to evaluate the
prognostic signiﬁcance of type I collagen synthesis and
degradation markers in lung cancer patients [19]. The
143 study patients had been variously treated with
radiation therapy with or without surgery, radiotherapy
plus chemotherapy, chemotherapy alone, surgery alone
or other treatment combinations. In multivariate
regression analysis, Hb level (P <0.002) and ESR (P
<0.02), in addition to other factors, were signiﬁcant
prognostic factors for OS when stratiﬁed with disease
stage and surgery.
Two retrospective studies conﬁrmed the importance
of Hb level as a prognostic factor in inoperable NSCLC
patients who underwent radiation therapy. In a study of
96 patients, most of whom had advanced NSCLC, pre-
treatment Hb level >15 g/dl was a signiﬁcant positive
prognostic factor for survival following primary radia-
tion therapy (P=0.0001), whereas the radiation dose
was not a signiﬁcant prognostic factor for survival [20].
In a study of 456 patients, 30 pretreatment variables
(ﬁve tumor-associated, ﬁve patient-associated, 20 initial
laboratory parameters) were evaluated as prognostic
factors for survival [21]. Results of univariate analysis
showed that 16 of the 30 variables, including Hb level
>12.7 g/dl (P <0.001), were favorable prognosticinﬂuences. Among the other factors favorably asso-
ciated with survival in the univariate analysis were low
disease stage (TNM stage I+II) (P <0.001), Eastern
Cooperative Oncology Group (ECOG) performance
status 0–1 (P <0.001), lactate dehydrogenase (LDH)
4200 U/l (P=0.005), serum gamma-glutamyl trans-
peptidase (GGT) 460 U/l (P=0.035), serum albumin
>3.5 g/dl (P=0.016), platelet count 4422/nl
(P=0.005) and lymphocyte count >2.0 nl (P=0.026).
Subsequent multivariate analysis showed that Hb
>12.7 g/dl (P=0.006), low stage of disease (P <0.001),
LDH 4200 U/l (P=0.035), serum GGT 460 U/l
(P=0.032), and lymphocyte count >2.0/nl (P=0.008)
remained signiﬁcant prognostic factors for survival.
3.2. Ovarian cancer
A retrospective analysis of 553 patients with histolo-
gically conﬁrmed epithelial ovarian cancer evaluated the
prognostic signiﬁcance of Hb levels before surgery [22].
In this group, 26% of patients had anemia (Hb <12 g/dl).
The 5-year OS rates were 34% and 47% in those with
and without anemia, respectively (P=0.0014). In a
univariate analysis, Hb level (P=0.0001), disease stage
(P <0.0001), residual tumor (P <0.0001), grading (P
<0.0001), age (P <0.0001), and histological sub group
(P=0.0016) were found to be signiﬁcantly associated
with OS. On multivariate analysis, disease stage (P
<0.0001), residual tumor (P <0.0001) and age
(P=0.0011) remained signiﬁcant factors inﬂuencing OS,
independent of each other; also, chemotherapy was
shown to be a signiﬁcant prognostic factor. Pretreat-
ment Hb level was not identiﬁed as a signiﬁcant inde-
pendent factor in this analysis. However, in a separate
analysis of a sub group of 203 patients with stage I or
stage II disease, Hb level was signiﬁcantly associated
with OS (rates 61% versus 74% for patients with Hb
levels <12 g/dl and 512 g/dl, respectively (P=0.037).
In multivariate analysis, Hb (P=0.050) and residual
tumor (P=0.018) were independent prognostic factors
for OS in this sub group. The authors concluded that
pretreatment anemia may identify those stage I and II
patients who are at increased risk of relapse.Table 1
Eﬀect of low Hb levels on overall survival in retrospective analyses of hematologic malignanciesRef. Patients N Eﬀect on OS Other eﬀects[10] Non-Hodgkin’s lymphoma 1077 Yes (uni/multi) PFS (univariate/multivariate)[11] Follicular lymphoma 987 Yes (univariate)[12] Mantle cell lymphoma 69 Yes (univariate) Response to therapy (univariate)[13] Mantle cell lymphoma 121 Yes (uni/multi)[14] Hodgkin’s disease 1681 Yes (univariate) Freedom from progression (multi)[15] Stage I/II subdiaphragmatic Hodgkin’s disease 87 Yes (uni/multi)[16] Pediatric Hodgkin’s disease 202 Not evaluated Event-free survival (uni/multi)[17] Relapsed/refractory AML 254 No Achievement of second remissionAML, acutemyeloid leukaemia; Hb, hemaglobin; multi, multivariate analysis; OS, overall survival; PFS, progression-free survival; uni, univariate analysis.14 S.J.-P. Van Belle / EJC Supplements Vol 2 No. 2 (2004) 11–19
Predictive factors associated with response to second-
line treatment were evaluated in 1185 platinum-pre-
treated patients with ovarian cancer [23]. These patients
had participated in European Organisation for
Research and Treatment of Cancer (EORTC) studies of
six diﬀerent chemotherapeutic agents: paclitaxel, epiru-
bicin, docetaxel, carboplatin, irinotecan and gemcita-
bine. Response results from the studies were obtained
for four speciﬁc variables: baseline Hb (WHO grade 0
versus grade51), serous histology (Yes/No), maximum
lesion size (45 versus >5 cm), and time from last
treatment (<6 months versus 56 months). Initial ana-
lysis showed that response to these agents was asso-
ciated with normal baseline Hb levels (WHO grade 0;
P=0.003), serous histology (P=0.001), tumor size 45
cm (P=0.02) and at least 6 months therapy-free interval
(P=0.001). A second analysis was then performed to
determine if the various predictors were independent of
each other. For this analysis, data for 11 variables from
four studies of paclitaxel, docetaxel and epirubicin
(n=704) were combined for univariate and multivariate
analysis of factors predictive of response. Ten of the 11
factors, including baseline Hb, were considered in the
regression analysis but, in the ﬁnal model, only three
remained as signiﬁcant independent predictors of
response: serous histology (P=0.009), number of dis-
ease sites (P=0.003), and tumor size (P=0.001). Thus,
in the setting of relapsed disease, tumor burden and
histology appear to be more important than Hb level in
predicting response to second-line treatment of ovarian
cancer.
3.3. Cervical cancer
Studies in patients with cervical cancer have also
demonstrated that Hb level is a signiﬁcant prognostic
factor for outcome. In a retrospective analysis of data
from 605 cervical cancer patients treated with radiation
therapy with or without chemotherapy at seven Cana-
dian institutions in 1989, 1990 and 1992, a baseline Hb
512.0 g/dl was shown by univariate analysis to be a
signiﬁcant prognostic factor for higher rates of OS
(P<0.003), local control of disease (P=0.002) and DFS
(P=0.005) [24,25]. On multivariate analysis, baseline
Hb was no longer a signiﬁcant prognostic factor, but
average weekly nadir Hb (AWNH) during radiation
therapy (P=0.0001) and tumor stage (P=0.0001),
intracavitary treatment (P=0.0004) and squamous his-
tology (P=0.0446) were signiﬁcant factors for outcome.
Further multivariate analysis, in which outcomes were
stratiﬁed by higher Hb (512.0 g/dl) versus lower Hb
(<12.0 g/dl) at baseline and during radiation therapy,
showed signiﬁcantly higher rates of overall survival
(P<0.0002) and lower rates of relapse (P=0.001), local
disease recurrence (P=0.008), and distant disease
recurrence (P=0.02) in the groups that achieved ormaintained the higher Hb levels compared with those
whose Hb decreased or remained low during treatment.
The investigators concluded that amelioration of
anaemia and maintenance of Hb levels above 12.0 g/dl
are vital to the success of radiation therapy in cervical
cancer patients.
An Australian study retrospectively examined the
eﬀect of anemia before and during chemo-irradiation in
57 patients with cervical carcinoma [26]. Mean Hb levels
at presentation and mean nadir Hb levels during treat-
ment were 12.9 and 11.1 g/dl, respectively, in patients
who achieved a complete clinical response, and 12.1 and
9.8 g/dl in those with treatment failure. Consistent with
the ﬁndings of the previous study, univariate analysis
identiﬁed the nadir Hb level as the most predictive fac-
tor for treatment failure (relative risk 1.92; P=0.015),
followed by disease stage (relative risk 0.51, P=0.074).
In a multivariate analysis, the nadir Hb remained the
only relevant prognostic factor predicting response to
chemo-irradiation, and only patients with nadir Hb
levels >11.0 g/dl throughout treatment had a >90%
chance of achieving a complete clinical response. The
investigators concluded that the nadir Hb level, rather
than the Hb level at the time of presentation, is highly
predictive of response to treatment.
3.4. Renal carcinoma
The prognostic factors for OS in advanced renal cell
carcinoma were determined in a retrospective analysis
of 670 patients who were treated with chemotherapy or
biological response modiﬁers in 24 clinical trials at the
Memorial Sloan-Kettering Cancer Center between 1975
and 1996 [27]. Median survival time was 10 months.
Upon multivariate analysis, a low Hb level was found to
be one of ﬁve pretreatment factors associated with
shorter OS. The other risk factors were poor Karnofsky
performance status (<80%), high ‘corrected’ serum
LDH, high serum calcium, and absence of prior
nephrectomy. Median OS was inversely related to the
number of these factors, ranging from 20 months in
patients with no risk factors to 4 months in those with
three or more risk factors.
In a study conducted in Japan, 111 patients who
underwent curative resection of renal cell carcinoma
were evaluated retrospectively to determine prognostic
factors for 5-year survival [28]. A univariate analysis
considered the prognostic signiﬁcance of 19 variables.
An Hb level >12 g/dl was signiﬁcantly associated with
higher 5-year survival rates (P=0.0129). Other factors
signiﬁcantly associated with longer survival included
body temperature <37 C (P=0.002), ESR 420 mm/h
(P=0.002), C-reactive protein (CRP) negative
(P=0.0005), ﬁbrinogen 4400 mg/dl (P=0.0002),
tumor size 45 cm (P=0.0389), Robson disease stage 1
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capsular involvement (P=0.0001) and mode of tumor
inﬁltration (P=0.0334). Upon multivariate analysis,
CRP (P=0.0126) and renal capsular involvement
(P=0.049) were the most important prognostic factors
for survival for at least 5 years following curative
resection.
3.5. Head and neck cancer
Considerable evidence suggests that tumor hypoxia is
common in head and neck tumors and that a relation-
ship exists between hypoxia and anemia in patients with
such tumors [29]. Additionally, numerous studies have
shown that tumor hypoxia and anemia adversely aﬀect
clinical outcome following radiation therapy or chemo-
irradiation therapy (reviewed by Kumar 2000 [29],
Vaupel 2001 [30], and Harrison 2002 [31]). Several
recent studies have examined the prognostic value of Hb
levels in patients with head and neck cancer undergoing
chemo-irradiation therapy. In a prospective study of
head and neck cancer patients treated with combined
chemo-irradiation therapy and surgery, results of a uni-
variate analysis showed that low Hb levels (<11.5 g/dl)
after treatment were signiﬁcantly associated with poorer
OS (P=0.0084) [32]. Other prognostic factors for
survival included tumor size (P=0.0088), response of
primary site to radiochemotherapy (P=0.045) and
response of lymph nodes to radiochemotherapy
(P=0.013).
A retrospective study of 191 patients with squamous
cell carcinoma of the oral cavity and oropharynx was
conducted using records from an Austrian hospital
for the years 1989–1998, inclusive. Patients had been
treated with mitomycin, 5-ﬂuorouracil and radiation
therapy, followed by surgery [33]. Starting in 1996,
patients with low Hb levels (<12.5 g/dl) before or
during chemo-irradiation additionally received epoetin
alfa to correct their anemia. For data analysis, patients
were classiﬁed according to whether their pretreatment
Hb was <14.5 g/dl and whether they had received
epoetin alfa during chemo-irradiation therapy. Results
of multivariate analysis showed that Hb level and the
use of epoetin alfa were independent prognostic factors
for response to chemo-irradiation and locoregional
tumor control (P <0.001). Patients with pretreatment
Hb levels >14.5 g/dl had signiﬁcantly higher complete
response, locoregional control, and OS rates than those
with pretreatment Hb levels <14.5 g/dl who had not
received epoetin alfa (P <0.05). Further, response,
locoregional control and OS rates in patients with low
Hb levels given epoetin alfa were signiﬁcantly higher
than those in patients with low Hb levels who had not
received epoetin alfa (P <0.001), and were equivalent
to those of patients with pretreatment Hb levels >14.5
g/dl (P >0.3). These ﬁndings suggested that low pre-
treatment Hb is a negative prognostic factor for patientswith squamous cell carcinomas of the oral cavity and
oropharynx, but that this can be reversed by adminis-
tration of epoetin alfa during chemo-irradiation
therapy.
3.6. Other solid tumours
In hormone-refractory prostate cancer, a Cox pro-
portional hazard model for survival time was used to
evaluate whether serial measurements of Hb level and
body weight improved the prognostic signiﬁcance of a
model based on prostate-speciﬁc antigen (PSA) and its
rate of change [34]. A total of 348 patients who partici-
pated in two Cancer and Leukemia Group B studies
were evaluated. Both Hb level and body weight were
signiﬁcantly related to survival (both P <0.0001). Serial
measurements of Hb levels and body weight were shown
to add signiﬁcant prognostic information to that
provided by PSA alone.
Taken together, these results indicate that Hb level is
a prognostic factor for survival in a number of solid
tumors, including NSCLC and ovarian, cervical, head
and neck and prostate cancers. Table 2 summarizes the
eﬀect of low Hb levels on OS in retrospective analyses
of solid tumors.4. Anemia and staging systems
Anemia is a common feature of both chronic
lymphocytic leukemia (CLL) and multiple myeloma and
is a component of the staging systems for both diseases.
The causes of anemia in CLL are multifactorial and
may include extensive bone-marrow inﬁltration by
lymphocytes, autoimmune hemolysis, hyperspleenism,
blood loss or anemia of chronic disease with associated
cytokine-driven inhibition of erythropoietin production
and diminished responsiveness of erythroid precursors to
erythropoietin [35]. In CLL patients, Hb levels <11 g/dl
designate Rai stage III disease, while levels <10 g/dl
designate Binet stage C independently of lympha-
denopathy or organomegaly. According to the National
Cancer Institute (NCI) guidelines, chemotherapy should
be considered for CLL patients with Hb levels <10 g/dl.
It has been suggested that if anemia is corrected by
administration of epoetin alfa, the disease may be
downstaged [35]. This could aﬀect treatment decisions,
with possible postponement of chemotherapy, and
perhaps even lead to improvement in survival. Such
potential beneﬁts remain to be investigated in randomized
clinical trials. In multiple myeloma, anemia is often
caused by inadequate production of erythropoietin [36],
but it may also occur as a result of bone-marrow inﬁltra-
tion by malignant cells, reduced survival of red blood cells,
renal insuﬃciency, cytokine production and the myelo-
suppressive eﬀects of chemotherapy [37]. In multiple16 S.J.-P. Van Belle / EJC Supplements Vol 2 No. 2 (2004) 11–19
myeloma patients, an Hb level >10 g/dl is a determin-
ing factor for stage I disease and Hb <8.5 is a deter-
mining factor for stage III [38]. In most patients, anemia
improves when the disease responds to chemotherapy
[39]. However, if this does not occur, or chemotherapy
is not required, the anemia may be treated with blood
transfusions or, given the inherent risks of the latter,
administration of epoetin alfa [39]. A small proportion
of patients, e.g. those with smouldering multiple
myeloma, have asymptomatic disease and do not
require chemotherapy. However, these patients often
develop anemia serious enough to require intervention
and may subsequently be given chemotherapy to
address the anemia. In such cases, epoetin alfa should
be considered as a possibility for avoiding, at least
temporarily, initiation of chemotherapy.5. Preclinical evidence
Several experimental studies provide evidence
supporting the prognostic signiﬁcance of Hb level. In
the rat 9L gliosarcoma model, administration of an Hb
solution reduced the level of tumor hypoxia [40]. The
response of the tumor to chemotherapy and radiation
therapy was assessed by determining the tumor growth
delay under conditions of anti-angiogenic therapy with
TNP-470 and minocycline alone or in combination with
an Hb solution with or without carbogen breathing.
Tumor response was strongly correlated with decreasing
tumor hypoxia. Speciﬁcally, tumor growth delay due to
carmustine (BCNU), doxorubicin or fractionated
radiation therapy was enhanced when these agents were
administered in combination with TNP-470 and mino-
cycline, and this eﬀect was further enhanced by the
addition of Hb solution with or without carbogenbreathing to the individual combinations. For example,
tumor growth delays were 4.8 days with radiation
therapy alone, 5.8 days with radiation plus TNP-470/
minocycline, 10.8 days with radiation plus TNP-470/
minocycline and the Hb solution and 13.3 days with
the previous combination plus carbogen breathing.
Comparable values for BCNU with treatment-related
increases in oxygenation were 5.3, 9.9, 10.4 and 16.4
days. These data highlight the fact that addition of
oxygenation-enhancing agents to radiation therapy or
some chemotherapeutic agents can improve therapeutic
response.
Similar results were obtained with polyethylene-
glycol (PEG) hemoglobin in the rat 13762 and murine
EMT-6 mammary carcinoma models [41]. Polyethylene-
glycol hemoglobin reduced tumor hypoxia before and
after administration of chemotherapy. Moreover, PEG
hemoglobin increased the tumour growth delay
produced in these models by cyclophosphamide, doxo-
rubicin, 5-ﬂuorouracil, BCNU and paclitaxel. This
beneﬁt of PEG hemoglobin was associated with a
concomitant reduction in lung metastases. The results of
the preclinical studies described suggest that increasing
tumor oxygenation may markedly enhance the
therapeutic response to cytotoxic chemotherapy and
radiation therapy in these models.
Another strategy for increasing Hb level is to admin-
ister epoetin alfa. The eﬀect of epoetin alfa on the anti-
tumor activity of cisplatin was evaluated in female
severe-combined immunodeﬁcient (SCID) mice with
human ovarian cancer xenografts [42]. One group of
mice had large ovarian cancer xenografts implanted on
the gonadal fat pad, whereas another group of SCID
mice had small subcutaneous ovarian cancer xenografts.
Animals in each group were given one of four treat-
ments: epoetin alfa 20 units three times per week,Table 2
Eﬀect of low Hb levels on overall survival in retrospective analyses of solid tumorsRef. Patients N Eﬀect on OS Other eﬀects[18] Extensive-stage NSCLC 2531 Yes (univariate) OS in subgroup with good PFS (multi)[19] Lung cancer 143 No OS when stratiﬁed with disease stage and surgery (multi)[20] Inoperable NSCLC 96 Yes (univariate) OS in subgroup with stage I/II disease[21] Inoperable NSCLC 456 Yes (uni/multi)[22] Ovarian cancer 553 Yes (univariate) OS in subgroup with stage I/II (multi)[23] Second/third-line treatment in
platinum-treated ovarian cancer1185 Not evaluated Response to therapy (univariate)[24] Cervical cancer 605 Yes (univariate) OS for average weekly nadir Hb (multivariate)[26] Cervical carcinoma 57 Not evaluated Nadir Hb predictive for treatment failure (uni/multi)[27] Advanced renal cell carcinoma 670 Yes (multivariate)[28] Curatively resected renal cancer 111 Yes (univariate)[32] Advanced head and neck cancer 43 Yes (univariate)[33] Head and neck cancer 191 Not evaluated Prognostic for response to chemoradiation
and locoregional control (multivariate)[34] HR prostate cancer 348 Yes (multivariate)AML, acute myeloid leukemia; Hb, hemoglobin; HR, hormone refractory; multi, multivariate analysis; NSCLC, non–small-cell lung cancer;
OS, overall survival; PFS, progression-free survival; uni, univariate analysis.S.J.-P. Van Belle / EJC Supplements Vol 2 No. 2 (2004) 11–19 17
cisplatin 5 mg/kg weekly, epoetin alfa plus cisplatin, or
phosphate-buﬀered saline control.
The growth of the large tumors was signiﬁcantly
delayed by cisplatin with or without epoetin alfa
compared with the control group (P <0.05). In these
animals, the addition of epoetin alfa did not
signiﬁcantly aﬀect the growth delay relative to cisplatin
alone (P=0.07). In contrast, signiﬁcantly greater tumor
regression was achieved with combined cisplatin plus
epoetin alfa compared with cisplatin alone in the SCID
mice with small subcutaneous tumors (P <0.05). Epoe-
tin alfa alone did not have any antitumor activity. The
beneﬁt of epoetin alfa was associated with a 25–35%
increase in hematocrit, which diﬀered signiﬁcantly from
the 2% decrease seen with saline control (P <0.01). In
comparison, the animals that received cisplatin
displayed a 20% reduction in hematocrit. Epoetin alfa
reduced the morbidity associated with cisplatin therapy
when performance status scores based on ﬁve objective
criteria associated with morbidity and mortality in
experimental mice (ruﬄed fur, weakness/lethargy,
weight loss, kyphotic hunched posturing and death)
were assessed after the ﬁrst (26 versus 17 points) and
second (43 versus 29 points) weeks of therapy. These
results demonstrate that epoetin alfa improves respon-
siveness of human ovarian cancer xenografts to cisplatin,
which is associated with an increase in hematocrit and
reduction in morbidity.6. Conclusion
Clinical evidence shows that Hb level is a prognostic
factor for OS and/or DFS in several hematological
malignancies and solid tumors. Hemoglobin level is also
a negative predictive factor for response to treatment, in
particular to chemotherapy in AML and mantle cell
lymphoma, and possibly in relapsing ovarian cancer.
This body of clinical evidence is supported by experi-
mental data in animal tumor models. Nevertheless, it is
important to recognize that the available clinical
evidence is based almost exclusively on retrospective
analyses of medical records. This underscores the need
for prospective clinical trials that are designed speciﬁ-
cally to ascertain whether Hb levels aﬀect treatment
outcome. In a 28-week multinational study designed to
explore the eﬃcacy of epoetin alfa on anemia and QOL
in anemic cancer patients receiving non-platinum-based
chemotherapy, a trend was observed suggesting that
epoetin alfa may improve survival [43]. Randomized
trials designed to conﬁrm a survival beneﬁt of epoetin
alfa are clearly needed. In conclusion, there is more than
one reason to pay attention to Hb levels in cancer
patients: not only is normalizing Hb important for
improving QOL, but it may also play a role in inﬂuencing
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